TOP TIERMARKET NEWSWIRE

News & sentiment

ROIVANT SCIENCES LTD (ROIV) — News & AI sentiment

ROIVANT SCIENCES LTD (ROIV) news roundup. 8 stories in the past week, 19 over 30 days. Average 30-day sentiment is 61.7/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 9 sales totalling $59.9M — net selling of $59.9M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

8

avg sentiment 62.8/100

30d stories

19

avg sentiment 61.7/100

Insider net (90d)

$59.9M

0 buys · 9 sells

Congress (90d)

0

0 buys · 0 sells

ROIV news in the last 24 hours, 7 days, 30 days and 90 days

How much ROIV coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ROIV stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	8	62.8/100	ROIV headlines →
Last 30 days	19	61.7/100	ROIV headlines →
Last 90 days	92	61.5/100	ROIV headlines →

Latest stories on ROIV

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow

Seeking Alpha58 · neutralproduct/pr

4d ago

Roivant Sciences price target raised to $62 from $55 at TD Cowen

The Fly64 · neutralanalyst

7d ago

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

Seeking Alpha58 · neutralproduct/pr

7d ago

Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

CNBC50 · neutralgeneral

7d ago

Roivant jumps after Phase 3 NIU data show brepocitinib pushed median time-to-failure past 48 weeks October 21, 2026

MarketChameleon74 · bullishproduct/pr

7d ago

Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win

Seeking Alpha74 · bullishproduct/pr

7d ago

Roivant Sciences stock surges on positive uveitis trial data

Investing.com Markets74 · bullishproduct/pr

Oct 21

Roivant Shares Gain on Positive Study Results for Non-Infectious Uveitis Treatment

MarketWatch67 · bullishproduct/pr

Oct 21

Roivant (ROIV) sets Nov. 9 results call and Dec. 9 investor day, putting near-term focus on updates for LISRAYA, IMVT-1402, and mosliciguat October 21, 2026

MarketChameleon52 · neutralgeneral

Oct 21

Roivant, Priovant report CLARITY-1 and CLARITY-2 trials meet primary endpoint

The Fly74 · bullishproduct/pr

Oct 21

Roivant reports strong Phase 3 data in uveitis

TipRanks74 · bullishproduct/pr

Oct 21

Roivant Sciences Ltd. (ROIV) files 8-K

SEC 8-K50 · neutralgeneral

Oct 21

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

Business Insider50 · neutralgeneral

Oct 21

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

GlobeNewswire74 · bullishproduct/pr

Oct 21

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

GlobeNewswire50 · neutralgeneral

Oct 21

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

Business Insider74 · bullishproduct/pr

Oct 21

Roivant Sciences added to Citi's 90-day catalyst watch

Seeking Alpha58 · neutralanalyst

Oct 13

Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences

The Fly63 · neutralanalyst

Oct 12

Roivant Sciences downgraded to Peer Perform from Outperform at Wolfe Research

The Fly34 · bearishanalyst

Oct 12

Cantor Fitzgerald reiterates Roivant Sciences stock rating

Investing.com Analyst Ratings50 · neutralanalyst

Sep 24

Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy

Seeking Alpha28 · bearishproduct/pr

Sep 23

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

StockTitan63 · neutralproduct/pr

Sep 23

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewswire63 · neutralproduct/pr

Sep 23

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha56 · neutralgeneral

Sep 22

Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test

Yahoo Finance63 · neutralanalyst

Sep 22

Open ROIV in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →